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Obesity is a major risk factor for venous thromboembolism (VTE), but it is unknown to what
extent weight change over time affects VTE risk.
Aims
To investigate the association between weight change and risk of incident VTE in a popula-
tion-based cohort with repeated measurements.
Methods
Participant data were collected from the Tromsø 3 (1986–87), 4 (1994–95), 5 (2000–01)
and 6 (2007–08) surveys. Subjects who attended two subsequent or more surveys were
included (n = 17802), and weight change between the surveys was calculated. Person-time
at risk was accrued from the second of two subsequent vists until the next survey, the date
of an incident VTE, migration, death or study end (December 31st 2012), whichever came
first. Cox regression models were used to calculate risk of VTE according to change in body
weight.
Results
There were 302 incident VTE events during a median of 6.0 years of follow-up. Subjects
who gained most weight (7.5–40.0 kg weight gain) had a 1.9-fold higher risk of VTE com-
pared to those with no or a moderate (0–7.4 kg) weight gain (HR 1.92; 95% CI 1.38–2.68).
The VTE risk by7.5 kgs over no or moderate (0–7.4 kg) weight gain was highest (HR 3.75;
95% 1.83–7.68) in subjects with baseline body mass index (BMI)30 kg/m2. There was a
joint effect of weight gain and baseline BMI on VTE risk. Those with BMI30 who gained
7.5 kgs had a 6.6-fold increased risk (HR 6.64; 95% CI 3.61–12.22) compared to subjects
with BMI <25 and no or moderate (0–7.4 kg) weight gain.
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Our findings imply that further weight gain is a considerable risk factor for VTE, particularly
in obese individuals.
Introduction
Overweight and obesity are major risk factors for venous thromboembolism (VTE). Results
from prospective cohorts have consistently shown a 2 to 3-fold increased risk of VTE in obese
subjects [1–7]. To date, the underlying mechanism for this association remains not fully
understood [8]. Although obesity is a shared risk factor for arterial and venous thrombosis, the
impact of body fat distribution and the cardiometabolic disturbances associated with central
obesity, differs for the association between obesity and arterial and venous thrombosis [2].
Whereas cardiometabolic disturbances secondary to obesity are of major importance in the
pathogenesis of myocardial infarction, other consequences of obesity, such as venous stasis,
may be of more importance for VTE [9].
Modifiable risk factors, such as obesity, may lead to an underestimation of true associations
between exposure and outcome in cohort studies. Analyses based on single [1–5] and repeated
[6, 7] measures of obesity, however, have displayed essentially similar risk estimates for VTE.
Although time-varying analyses based on repeated measures gives a more accurate estimate of
the association between a modifiable risk factor and outcome, it does not assess the impact of
intra-individual changes of a risk factor on the outcome. To our knowledge, no previous study
have investigated whether changes in body weight are associated with risk of VTE. Consider-
ing the linear relationship between obesity measures and VTE risk [8], it is assumed that vol-
untary weight reduction in overweight persons will be beneficial, whereas involuntary weight
loss (e.g. due to cancer or other diseases) may have an adverse effect on VTE risk. Conversely,
weight gain may lead to increased risk of VTE. Actually, several studies have shown that weight
gain, weight loss and/or fluctuations in body weight are all associated with future risk of arte-
rial cardiovascular diseases as well as all-cause mortality [10–17]. Even within the “normal”
weight range, weight gain is associated with higher risk of coronary heart disease [15].
In the present study, we aimed to investigate whether weight change was associated with
VTE risk, and to elucidate whether weight change was a risk factor for VTE independent of
obesity status. Therefore, we assessed the risk of VTE according to changes in body weight
within a prospective population-based cohort with four repeated measurements 6–8 years
apart, with and without adjustment for the attained body mass index.
Materials and Methods
Study population
As described previously [2], the Tromsø Study is a single-center, prospective, population-
based health study, with repeated health surveys of inhabitants in Tromsø, Norway. The third
survey was carried out in the period 1986–1987, the fourth in 1994–1995, the fifth in 2000–01
and the sixth in 2007–08. Members of the population living in the municipality of Tromsø,
Norway, were invited to participate in these surveys. The overall participation rate was high,
ranging from 66% to 78% in the different surveys. Subjects who attended two or more subse-
quent surveys were included in our study. A detailed description of study participation has
been published previously [18]. Subjects with a history of VTE at baseline (n = 185) were
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excluded from the study. Thus, our study population consisted of 17 802 unique subjects, aged
25–89 years. The study was approved by the Regional Committee of Medical and Health
Research Ethics, and all participants gave their informed written consent to participate.
Measurements
Exposure information was collected by self-administered questionnaires, physical examination
and non-fasting blood samples, as described in detail previously [2]. Body height and weight
was measured by study personnel with subjects wearing light clothing and no shoes. Informa-
tion on cancer before and during follow-up was obtained from the cancer registry of Norway.
The cancer registry is considered complete and valid, and evaluations have reported 98.8%
completeness, with 94% microscopically confirmed diagnoses [19].
Outcome assessment of venous thromboembolism
All first lifetime VTE events during follow-up were recorded from the date of enrollment to
the end of the study period. The VTE events were classified as unprovoked or provoked on the
basis of provoking factors at the time of diagnosis. A detailed description of the outcome
assessment has previously been published elsewhere [5]. In short, all incident VTEs in the
region were identified using the hospital discharge diagnosis registry, the autopsy registry and
the radiology procedure registry from University Hospital of North Norway (UNN), which is
the sole provider of relevant diagnostic radiology in the area. All events were validated by
trained personnel, requiring signs and symptoms of DVT or PE combined with objectivecon-
firmation by radiological procedures, which resulted in treatment initiation unless contraindi-
cations were specified.
Statistical analyses
Statistical analyses were carried out using Stata version 14 (Statacorp LP). Weight change
between two subsequent visits was calculated, and subjects were then followed from the date of
the second visit until a VTE event, the next visit (or the median date of visit for the next survey
if the survey was not attended), migration, death or study end (December 31st 2012), which-
ever came first. Individuals who attended three or four subsequent visits contributed with mul-
tiple observation periods (Fig 1), yielding 27 376 observations in total. A detailed description
of study participation and follow-up is presented in the supplementary material.
Time-varying cox-proportional hazards regression models were used to estimate hazard
ratios (HR) with 95% confidence intervals (CI) for VTE across categories of change in body
weight. Subjects with no or a moderate weight gain (0–7.5 kg) were used as reference, and
Fig 1. Overview of exposure and follow-up. Exposure was recorded as the change in body weight between two
subsequent surveys. Subjects were followed until the date of a third survey or December 31, 2012. Subjects who
attended three or more subsequent surveys thus contributed with multiple exposures and follow-up periods.
doi:10.1371/journal.pone.0168878.g001
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were compared with subjects with any weight loss (-0.1 to -56.6 kg) and subjects with a weight
gain7.5 kg (the top 15 percent). We also performed analyses across quintiles of changes in
body weight. Analyses were performed in three adjustments models, using age as time-scale.
Model 1 was adjusted for sex, whereas model 2 included the attained BMI measured at the sec-
ond visit. Other potential confounders such as smoking, systolic blood pressure, triglycerides,
HDL-cholesterol and self-reported diabetes mellitus were not associated with VTE in the
Tromsø Study [20, 21], and were therefore not included in the multivariable models. The pro-
portional hazard assumption was verified by evaluating the parallelism between the curves of the
log–log survivor function for different categories of the variables. Statistical interactions between
weight change, BMI and the other variables in the models were tested, and there was a significant
interaction between BMI and weight change. We therefore stratified the study population
according to BMI status at the start of the weight change interval (<25 vs 25–29.9 and30 kg/
m2). We also performed analyses separately for provoked and unprovoked VTE. Because of lim-
ited statistical power, subjects with BMI25 were merged into one strata in these analyses.
Cancer is a strong risk factor for VTE, and is often associated with involuntary weight loss.
The risk of VTE is particularly high immediately before [22] and the first years after [23] can-
cer diagnosis. For sensitivity purposes, we therefore performed analyses where subjects with
incident cancer were censored six months prior to the cancer diagnosis, but only if the time
span between cancer and VTE diagnosis was less than five years. As weight variability also is
related to mortality [12, 14], the observed associations could be influcenced by competing risk
by death. We therefore applied The Fine–Gray model as a sensitivity analysis to account for
death as a competing event [24].
Results
The mean age at study entry was 54±14 years and 46.2% (n = 12,661) were men. The mean
weight change in the study population was +2.6 kg, and the weight change in the cohort dis-
played a normal distribution (Fig 2).
Characteristics of subjects at study entry across weight change intervals are shown in
Table 1. Subjects who experienced the most profound weight gain (7.5 kg or more) had the
lowest mean age and the highest BMI at entry, while subjects in the middle interval (0–7.4 kg
weight gain) were oldest and had the lowest BMI and percentage of smokers at study entry.
The distribution of traditional cardiovascular risk factors at study entry were essentially similar
across categories of weight change, except for a higher prevalence of diabetes among subjects
who experienced weight loss. There were 302 incident VTEs during a median follow-up of 6.0
years, of which 120 (40%) were classified as unprovoked. The overall crude incidence rate was
1.8 (95% CI 1.6–2.1) per 1000 person-years.
Risk estimates for VTE according to weight change are shown in Table 2. Subjects with the
highest weight gain (7.5 kg) had a 1.9-fold increased risk of VTE (HR 1.93; 95% CI 1.38–
2.68), and this risk was modestly attenuated after adjustment for BMI (HR 1.63, 95% CI 1.15–
2.30 In stratified analyses, the risk of VTE according to weight change was most pronounced
among obese subjects (baseline BMI30 kg/m2). In obese subjects, weight gain 7.5 kg was
associated with a 3.8-fold increased risk of VTE (HR 3.75; 95% CI 1.83–7.68). Overall, there
was a trend towards a slightly increased VTE risk for subjects who lost weight (56.6–0.1 kg
weight loss) (HR 1.15, 95% CI 0.89–1.49 in the model adjusted for BMI). The risk was most
pronounced in overweight subjects (HR 1.43; 95% CI 0.95–2.13).
Corresponding analyses across quintiles of change in body weight (S1 Table) yielded similar
results, with a somewhat stronger association for the quintile with the highest weight loss (HR
1.66; 95% CI 1.07–2.60.
Weight Change and Risk of VTE
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Fig 2. Distribution of weight change (in kgs) in the study population
doi:10.1371/journal.pone.0168878.g002
Table 1. Baseline Characteristics of the Study Population Across Categories of Weight Change
Category of Weight change
56.6–0.1 kg loss 0–7.4 kg gain 7.5–40.0 kg gain
n 8547 14331 4501
Men, % 48.3 (4124) 45.9 (6581) 43.5 (1958)
Age, years 59.0 ±14.3 52.9 ± 13.3 47.1 ±12.5
BMI, kg/m2 24.7 ±3.9 25.7 ±3.6 28.6 ±4.3
Body weight, kg 70.2 ± 13.2 73.8 ±12.8 83.3 ±14.1
Smoking, % 36.1 (3087) 31.6 (4530) 28.4 (1280)
Systolic blood pressure, mm Hg 139 ± 23 136 ±20 136 ±19
Total cholesterol, mmol/L 6.0 ±1.2 6.1 ±1.2 6.2 ±1.2
HDL cholesterol, mmol/L 1.6 ± 0.4 1.5 ±0.4 1.4 ±0.4
Triglycerides, mmol/L 1.4 ± 0.8 1.5 ±1.0 1.8 ±1.2
Diabetes mellitus, % 5.5 (468) 1.7 (238) 1.8 (81)
Values are means ±1 SD or percentage with numbers in brackets.
doi:10.1371/journal.pone.0168878.t001
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Hazard ratios for VTE according to weight change across BMI strata are presented in Fig 3.
Compared to normal-weight subjects (baseline BMI<25 kg/m2) with no or moderate weight
gain, obese subjects with the highest weight gain had a 6.6-fold increased risk of VTE (HR
6.64; 95% CI 3.61–12.22).
To investigate whether weight change had differential associations on risk of unprovoked
and provoked VTE, we estimated hazard ratios for the two VTE types separately (Table 3). We
found no significant associations between weight change and provoked VTE in any BMI strata.
Weight gain (7.5 kg) was associated with a 2.6-fold increased risk of unprovoked VTE
among normal-weight individuals (HR 2.57; 95% CI 1.23–5.37), and a 2.1-fold increased risk
among overweight/obese (BMI25 kg/m2) (HR 2.11; 95% CI 1.13–3.95). The risk estimates
were not affected by adjustment for attained BMI.
In order to investigate whether weight change attributed to cancer influenced the VTE risk,
we repeated the analyses with incident cancer as a competing event (Table 4). In these analyses,
the risk estimates for unprovoked VTE remained essentially unchanged, while the association
between weight loss and provoked VTE among subjects with BMI >25 was more pronounced
(HR adjusted for BMI 1.96, 95% CI 1.22–3.15). In contrast, the risk estimates for weight loss
were slightly attenuated and no longer statistically significant when competing risk by death
was taken into account (Table 4).
Discussion
In the present study, weight gain was associated with higher risk of VTE, which was mediated
by an increased risk of unprovoked VTE events. The risk estimates were only modestly affected
by adjustment for the attained BMI. Weight gain showed strongest association with VTE risk
Table 2. Incidence Rates (IR) and Hazard Ratios (HR) with 95% Confidence Intervals (CI) for Venous Thromboembolism (VTE) According to
Changes in Body Weight, Stratified by BMI at the Start of the Weight Change Interval
Body weight change Person-years of follow-up Events IR*(95% CI) Model 1a Model 2b
HR (95% CI) HR (95% CI)
All subjects
56.6–0.1 kg loss 49 050 120 2.45 (2.05–2.93) 1.06 (0.83–1.37) 1.15 (0.89–1.49)
0–7.4 kg gain 87 767 132 1.50 (1.27–1.78) Ref Ref
7.5–40.0 kg gain 28 022 50 1.78 (1.35–2.35) 1.93 (1.38–2.68) 1.63 (1.15–2.30)
BMI <25
23.9–0.1 kg loss 24 846 30 1.21 (0.84–1.73) 0.74 (0.47–1.17) 0.78 (0.47–1.29)
0–7.4 kg gain 54 616 53 0.97 (0.74–1.27) Ref Ref
7.5–39.0 kg gain 16 815 19 1.13 (0.72–1.77) 1.86 (1.09–3.16) 1.74 (0.96–3.18)
BMI 25–29.9
31.6–0.1 kg loss 18 028 65 3.61 (0.28–4.60) 1.24 (0.87–1.76) 1.43 (0.95–2.13)
0–7.4 kg gain 27 556 63 2.29 (1.79–2.93) Ref Ref
7.5–40.0 kg gain 8 639 15 1.74 (1.05–2.88) 1.21 (0.69–2.15) 1.00 (0.53–1.89)
BMI30
56.6–0.1 kg loss 6 176 25 4.05 (2.74–5.99) 1.24 (0.66–2.33) 1.01 (0.51–2.00)
0–7.4 kg gain 5 584 16 2.87 (1.76–4.68) Ref Ref
7.5–33.0 kg gain 2 567 16 6.23 (3.82–10.17) 3.75 (1.83–7.68) 4.70 (2.17–10.18)
*Crude incidence rates per 1000 person-years
a Model 1: Age as time-scale, adjusted for sex
b Model 2: Model 1 + adjusted for attained BMI
doi:10.1371/journal.pone.0168878.t002
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in already obese subjects, suggesting a joint effect of baseline BMI and weight gain. We also
found an unexpected slightly increased risk of provoked VTE by weight loss in overweight and
obese subjects. The association between weight loss and risk of provoked VTE was stronger
when subjects who developed cancer were censored six monts prior to the cancer diagnosis,
but was attenuated and no longer significant in competing risk by death analysis.
Weight gain is robustly associated with a variety of negative health outcomes, including car-
diovascular disease [25], diabetes [10] and hypertension [11]. Accordingly, we found that
weight gain was associated with increased risk of VTE, particularly among obese subjects. As
there is a linear relationship between obesity and VTE risk, it is not surprising that increase in
body weight increased the risk of VTE. The prothrombotic changes seen in individuals with
obesity may contribute to the VTE risk by weight gain. Population-based studies have shown
that chronic inflammation, assessed by CRP, is consistently associated with obesity [26, 27],
and inflammation stimulates synthesis of plasminogen activator inhibitor 1 (PAI-1), tissue fac-
tor (TF), fibrinogen and potentially other factors involved in the coagulation cascade [28, 29].
Fig 3. Hazard Ratios for Venous Thromboembolism According to Changes in Body Weight and Body Mass Index Measured at the Start
of the Weight Change Interval. Subjects with BMI <25 kg/m2 and 0–7.4 kg weight gain were used as reference. Age as time-scale, adjusted for
sex.
doi:10.1371/journal.pone.0168878.g003
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Plasma levels of PAI-1 and factor VIII are elevated in obesity [30], and high levels of these fac-
tors have been associated with increased VTE risk in several studies [31, 32]. Recently, we have
reported that chronic inflammation, assessed by repeated measures of CRP, was associated
with increased VTE risk and partly explained the association between obesity and VTE risk,
particularly in women [33]. Although excessive amounts of certain clotting factors and lack of
inhibitors have been associated with increased risk of VTE [34], activation of coagulation with
subsequent thrombus formation occurs only after initiation of the coagulation cascade in the
presence of TF [35]. Adipokines are a group of hormone-like substances secreted from adipose
tissue, which interact with the coagulation system in various ways [36] and are suggested to be
involved in the pathogenesis of obesity-related VTE [8]. Leptin induces TF expression [37],
while adiponectin acts in an opposite way [38]. Recently, Kimura and co-workers showed that
weight gain was associated with increased leptin levels and decreased levels of adiponectin,
independently of the attained BMI [39]. However, no study has yet investigated the role of adi-
pokines in VTE.
In the present study, most of the observed VTE risk by weight gain was independent of the
attained BMI, suggesting that the weight gain was more important for the VTE risk than the
resulting state of obesity. Nevetheless, the negative effects of weight gain were more pro-
nounced among subjects with BMI30 kg/m2 indicating that the combination of obestity and
further weight gain yielded a higher risk than the two components separately. According to
the thrombosis potential model [40], the effect of venous stasis seen in obese individuals [9]
combined with other possible procoagulant mechanisms due to adipose tissue growth may
explain this phenomenon.
Table 3. Crude Incidence Rates (IR) and Hazard Ratios (HR) with 95% Confidence Intervals (CI) for Provoked and Unprovoked Venous Thrombo-
embolism (VTE) According to Changes in Body Weight. Stratified According to BMI at the start of the weight change interval.
Body weight change Person-years of
follow-up
Events IR* Model 1a Model 2b
HR (95% CI) HR (95% CI)
Provoked VTE
BMI <25
23.6–0.1 kg loss 25 044 21 0.84 (0.55–1.29) 0.96 (0.54–1.70) 1.16 (0.61–2.21)
0–7.4 kg gain 54 813 30 0.55 (0.38–0.78) Ref Ref
7.5–30.2 kg gain 16 871 8 0.47 (0.24–0.95) 1.35 (0.61–2.96) 1.06 (0.44–2.55)
BMI25
56.6–0.1 kg loss 24 423 60 2.46 (1.91–3.16) 1.38 (0.94–2.03) 1.48 (1.00–2.21)
0–7.4 kg gain 33 260 47 1.41 (1.06–1.88) Ref Ref
7.5–40.0 kg gain 11 232 16 1.42 (0.87–2.33) 1.71 (0.96–3.04) 1.50 (0.82–2.73)
Unprovoked VTE
BMI <25
23.6–0.1 kg loss 25 044 9 0.42 (0.28–0.63) 0.47 (0.22–1.03) 0.41 (0.17–0.96)
0–7.4 kg gain 54 813 23 0.36 (0.19–0.69) Ref Ref
7.5–30.2 kg gain 16 871 11 0.65 (0.36–1.18) 2.57 (1.23–5.37) 3.07 (1.33–7.08)
BMI25
56.6–0.1 kg loss 24 423 30 0.96 (0.68–1.36) 1.00 (0.60–1.67) 0.97 (0.57–1.64)
0–7.4 kg gain 33 260 32 1.23 (0.86–1.76) Ref Ref
7.5–40.0 kg gain 11 232 15 1.34 (0.81–2.22) 2.11 (1.13–3.95) 2.15 (1.10–4.21)
*Crude incidence rates per 1000 person-years
a Model 1: Age as time-scale, adjusted for sex
b Model 2: Model 1 + adjusted for attained BMI
doi:10.1371/journal.pone.0168878.t003
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Weight loss and weight variability is associated with increased risk of cardiovascular dis-
ease, overall and cardiovascular mortality [12–14]. However, several reviews and meta-analy-
ses have pointed out that the effects of intentional weight loss on these outcomes are uncertain
[16, 41, 42], and confounding by concomitant illness may be of importance. The observed
increase in risk of provoked VTE by weight loss in our cohort was not attenuated by exclusion
of subjects with cancer, suggesting that cancer development did not contribute profoundly to
the apparent association between weight loss and VTE risk. However, other chronic diseases
associated with increased mortality, assessed by competing risk by death analyses, attenuated
the association between weight loss and VTE risk. Thus, it is likely to assume that other con-
comitant illnesses inducing weight loss would affect the association.
The main strengths of our study are the prospective design, objective measurement of expo-
sure data by trained personnel and the validation of VTE events. All hospital-care in the region
is exclusively provided by a single hospital, which facilitates the completeness of our outcome
registry. Some limitations should be considered. The interval between visits was six to seven
Table 4. Hazard Ratios (HR) with 95% Confidence Intervals (CI) for Provoked and Unprovoked Venous Thromboembolism According to Changes
in Body Weight, Competing Risk by Cancer and Competing risk by Death Analysis
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doi:10.1371/journal.pone.0168878.t004
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years, and there would likely be some degree of exposure misclassification as subjects may
have gained and lost weight between visits. Even though body weight was measured in a stan-
dardized way, variation in clothing and the time of day the examination took place might have
introduced measurement bias. In addition, especially subjects with the greatest weight change
could be prone to further weight change during follow-up, which could lead to an overestima-
tion of the true associations due to differential misclassification. Further, we did not know the
exact causes of weight variation, although we included models where cancer patients were cen-
sored and decreased survival was taken into account. Despite this, residual confounding could
still be an issue, especially for the unexpected asssociations between weight loss and VTE risk.
In conclusion, our study suggests that weight gain, independent of attained BMI, is a risk
factor for VTE. The risk of VTE associated with weight gain was particularly high in already
obese individuals. Surprisingly, we also found a slightly increased risk of provoked VTE in sub-
jects with weight loss.
Supporting Information
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